For UA/NSTEMI patients in whom PCI has been selected as a postangiography management strategy, it is reasonable to administer an IV GP IIb/IIIa inhibitor (abciximab, eptifibatide, or tirofiban) if not started before diagnostic angiography, particularly for troponin-positive and/or other high-risk patients.55,58 (Level of Evidence: A) 2011 recommendation remains current. 2. For UA/NSTEMI patients in whom PCI is selected as a management strategy, it is reasonable to omit administration of an IV GP IIb/IIIa inhibitor if bivalirudin was selected as the anticoagulant and at least 300 mg of clopidogrel was administered at least 6 hours earlier.55,57 (Level of Evidence: B) 2007 recommendation remains current. 3. If LVEF is less than or equal to 0.40, it is reasonable to perform diagnostic angiography.111 114 (Level of Evidence: B) 2007 recommendation remains current. 4. If LVEF is greater than 0.40, it is reasonable to perform a stress test.111 (Level of Evidence: B) 2007 recommendation remains current. Class IIb 1. Platelet function testing to determine platelet inhibitory response in patients with UA/NSTEMI (or, after ACS and PCI) on P2Y12 receptor inhibitor therapy may be considered if results of testing may alter management.115 119 (Level of Evidence: B) modified ( thienopyridine replaced with P2Y12 receptor inhibitor ). 2. Genotyping for a CYP2C19 loss of function variant in patients with UA/NSTEMI (or, after ACS and with PCI) on P2Y12 receptor inhibitor therapy might be considered if results of testing may alter management.19 22,25,27,120 (Level of Evidence: C) modified ( thienopyridine replaced with P2Y12 receptor inhibitor ). Class III: No Benefit 1. IV fibrinolytic therapy is not indicated in patients without acute ST-segment elevation, a true posterior MI, or a presumed new left bundle-branch block.121 (Level of Evidence: A) 2007 recommendation remains current. 